FDA Nod For MRK’s Keytruda, SGMO Soars On Gene Therapy Deal, OMER Catches Eyes – Nasdaq
|
FDA Nod For MRK's Keytruda, SGMO Soars On Gene Therapy Deal, OMER Catches Eyes
Nasdaq Shares of Sangamo Therapeutics Inc. (SGMO) were up 44.83% to $6.30 in extended trading on Wednesday, following a global collaboration with Pfizer Inc. (PFE) for Hemophilia A gene therapy. The agreement also covers SB-525, one of Sangamo's four lead … |
